Endologix To Report Second Quarter 2013 Financial Results On July 30, 2013

IRVINE, Calif., July 18, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its second quarter 2013 financial results, which will take place on Tuesday, July 30, 2013 after the close of the market.

Endologix will hold a conference call on Tuesday, July 30, 2013 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.endologix.com .

After the live webcast, a transcript of the call will remain available online from the investor relations page of Endologix's website, www.endologix.com , through August 30, 2013. In addition, a telephonic replay of the call will be available until August 6, 2013. The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers. Please use the replay pin number 418116.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com .
CONTACT: COMPANY CONTACT:         Endologix, Inc.         John McDermott, CEO         Shelley Thunen, CFO         (949) 595-7200         www.endologix.com                  INVESTOR CONTACTS:         The Ruth Group         Nick Laudico (646) 536-7030         Zack Kubow (646) 536-7020

If you liked this article you might like

Endologix Poised for a Potentially Volatile Breakout

5 Stocks Trending Close to Major Breakouts

5 Stocks Set for Explosive Breakouts

These 5 Stocks Under $10 Could Make You a Lot of Money

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains